市場調査レポート
商品コード
1154789
肝細胞がん (HCC) のデジタルマーケティング動向Digital Marketing Trends in Hepatocellular Carcinoma |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
肝細胞がん (HCC) のデジタルマーケティング動向 |
出版日: 2022年09月23日
発行: GlobalData
ページ情報: 英文 30 Pages
納期: 即納可能
|
Keytruda.com (Merck & Co. の子会社) は、米国の肝細胞がん(HCC)患者サイト全体で最高のトラフィックを達成し、2021年8月から2022年7月までに210万回の訪問を記録しました。これにBristol Myers Squibb(BMS)のOpdivo.com(120万回)、GenentechのTecentriq.com(49万7,000回)が続きました。これらのサイトへのトラフィックは、直接のソースから発生したものが最も多く、次いでオーガニックトラフィック、リフェラルトラフィックとなっています。
当レポートでは、米国の肝細胞がん (HCC) 市場における昨今の競合情勢について分析し、主要企業が患者・医療専門家 (HCP) 向けに展開しているWebサイト・ソーシャルメディア・モバイルアプリなどの傾向や、主要企業の具体的な展開状況、カナダ・英国・EU諸国 (イタリア、フランス、ドイツ、スペイン) を含めた全体的動向、といった情報を取りまとめてお届けいたします。
Merck & Co.'s Keytruda.com achieved the highest traffic across US hepatocellular carcinoma (HCC) patient sites, with 2.1 million visits from August 2021 to July 2022. This was followed by Bristol Myers Squibb's (BMS's) Opdivo.com (1.2 million visits) and Genentech's Tecentriq.com (497,000 visits). The highest proportion of traffic to these sites originated from direct sources, followed by organic and referral traffic.
Between August 2021 and July 2022, BMS spent the most on digital display advertising (DDA) for Opdivo.com at $724,000, followed by Merck & Co. for Keytruda.com at $539,000. Keytruda.com was supported by the most paid keywords at 6,460, followed by Opdivo.com at 3,360. For branded healthcare professional (HCP) sites in the US, Merck & Co.'s Keytrudahcp.com had the highest number of visits, with 330,000 total visits, followed by Genentech's Tecentriq-hcp.com (263,000 visits). The highest proportion of traffic to these sites originated from direct and organic sources. The DDA for HCP sites in the US was focused on other indicators, with few ads detected for HCC. Between August 2021 and July 2022, most HCC social media posts from pharma in the US were from Eisai, Exelixis, and AstraZeneca corporate accounts, with posts from the Exelixis Facebook account achieving the highest interaction. No apps for HCC patients were detected from pharma in the US. In Europe and Canada (EUCAN), branded sites for HCC products were detected mainly in Germany. However, no notable traffic or paid search engine optimization (SEO) was detected. Most branded information is hosted on corporate medical information websites. Between August 2021 and July 2022, the most HCC social media posts from pharma in EUCAN were from Bayer, MSD, and Roche corporate accounts. No apps for HCC patients were detected from pharma in EUCAN.
Countries include the US, 4EU (Italy, France, Germany, and Spain), the UK, and Canada (EUCAN).